News

BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients

Study represents first data with BCX9930 in C3G patientsRESEARCH TRIANGLE PARK, N.C., Aug. 26, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals,…

2 years ago

89bio Presents Positive Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at European Society of Cardiology Congress 2022

-Results featured in a late-breaking oral presentation- -Treatment with pegozafermin demonstrated consistent and significant benefit in triglyceride (TG) reduction as…

2 years ago

PCI Biotech: Invitation to first-half year 2022 results presentation

Oslo, Norway, 26 August 2022 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's first-half year…

2 years ago

Philips spotlights integrated, data-driven cardiology solutions at ESC 2022

Clinicians using Ultrasound Workspace A clinician using Ultrasound Workspace Philips SmartSpeed MR software image August 26, 2022 Philips AI-powered interventional…

2 years ago

Mendus AB: Mendus AB (publ) interim report April – June 2022

Progress made throughout the second quarter puts the company in a strong position to deliver meaningful clinical progress in the…

2 years ago

Disclosure of received notification from The Goldman Sachs Group, Inc. and NN Group N.V.

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 26 August 2022 – 8AM CET Disclosure of received notification from The Goldman Sachs Group,…

2 years ago

Bone Therapeutics to host Extraordinary General Meeting on 26 September 2022

REGULATED INFORMATION Preliminary documents for the Extraordinary General Meeting have been made available on company’s website Mont-Saint-Guibert, Belgium, 26 August 2022,…

2 years ago

IBA qualifies as the only supplier for second round of tender to provide ten proton therapy units across Spain        

Louvain-La-Neuve, Belgium, 26 August, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s…

2 years ago

Mendus AB: Mendus announces financing commitments totaling up to SEK 250 million with Van Herk Investments and Negma Group

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company addressing tumor recurrence through cell-based immunotherapies, today announces that it has entered…

2 years ago